EQS-News: Eckert & Ziegler Begins Production of Actinium-225, Paving the Way for GMP-Grade Supply
|
EQS-News: Eckert & Ziegler SE
/ Key word(s): Product Launch
Berlin, 02 December 2024. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) today celebrates the successful start of Actinium-225 (Ac-225) production, addressing the global shortage of this critical radionuclide. This milestone marks a major success of the common project with the Nuclear Physics Institute of the Czech Academy of Sciences (ÚJF). The test production demonstrated that the choice of technology was appropriate to achieve the expected parameters of the product. In parallel with production, Eckert & Ziegler has commenced the validation process to produce GMP-grade Ac-225, crucial for clinical and commercial use. It is expected to become available in the first half of 2025, unlocking new opportunities for pharmaceutical companies developing alpha-emitting radiopharmaceuticals. The production facility employs innovative cyclotron-based methods to generate Ac-225 from Radium-226, marking a pivotal advancement in isotope production. “This milestone underscores our commitment to advancing cancer treatment through the reliable supply of radioisotopes,” said Dr. Lutz Helmke, Managing Director of Eckert & Ziegler Radiopharma GmbH. “The commencement of Ac-225 production not only addresses the current shortage but also fortifies Eckert & Ziegler’s position as a key player in the future of radioligand therapy.” The successful start of Ac-225 production is a direct result of the close collaboration between Eckert & Ziegler and the ÚJF. Drawing on decades of expertise in nuclear research and radiopharmaceutical development, ÚJF has played a crucial role in designing and optimizing this production pathway for Ac-225. Incorporating custom-engineered solutions by Isotope Technologies Dresden GmbH, Eckert & Ziegler’s hot cell division, the production process is designed to be efficient and sustainable. The start of production positions Eckert & Ziegler at the forefront of the radiopharmaceutical industry's transformation, offering a reliable and scalable source of Ac-225 for clinical development and commercial manufacturing. About Eckert & Ziegler SE Contact
02.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Eckert & Ziegler SE |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | +49 30 941084-138 |
| Fax: | +49 30 941084-0 |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Indices: | SDAX, TecDax, |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2041567 |
| End of News | EQS News Service |
|
|
2041567 02.12.2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 168,71 | 178,49 | 176,14 | 180,44 | 222,26 | 246,09 | 290,00 | |
| EBITDA1,2 | 32,14 | 43,13 | 44,64 | 57,04 | 55,52 | 58,83 | 0,00 | |
| EBITDA-Margin3 | 19,05 | 24,16 | 25,34 | 31,61 | 24,98 | 23,91 | 0,00 | |
| EBIT1,4 | 23,39 | 32,06 | 33,69 | 47,45 | 44,54 | 45,45 | 60,00 | |
| EBIT-Margin5 | 13,86 | 17,96 | 19,13 | 26,30 | 20,04 | 18,47 | 20,69 | |
| Net Profit (Loss)1 | 16,89 | 22,48 | 23,11 | 34,66 | 29,75 | 26,77 | 0,00 | |
| Net-Margin6 | 10,01 | 12,60 | 13,12 | 19,21 | 13,39 | 10,88 | 0,00 | |
| Cashflow1,7 | 21,21 | 40,43 | 36,79 | 33,86 | 34,30 | 47,40 | 0,00 | |
| Earnings per share8 | 0,78 | 1,07 | 1,11 | 1,66 | 1,41 | 1,26 | 1,54 | |
| Dividend per share8 | 0,30 | 0,42 | 0,45 | 0,50 | 0,50 | 0,05 | 0,50 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Forvis Mazars
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Eckert & Ziegler | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 565970 | DE0005659700 | SE | 943,84 Mio € | 25.05.1999 | Halten | 9F4MJGG3+WR |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 27,52 | 26,29 | 1,05 | 49,04 | 4,27 | 19,91 | 3,84 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,50 | 0,05 | 0,50 | 1,12% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 18.06.2025 | 13.05.2025 | 08.08.2025 | 14.11.2024 | 27.03.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +5,41% | +14,32% | +21,44% | +24,09% | +675,30% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
